SF5187

Purpose

• Establish a prohibition on using step therapy protocols for the treatment of neurological conditions. The bill would require health plans that cover neurological treatments to ensure patients are not forced to try lower-tier or stepwise therapies before using FDA-approved drugs that are on the plan’s formulary when those drugs are appropriate under FDA indications and clinical guidelines.

Key Definitions

• Neurological condition: A disorder, whether from injury or illness, that causes impairment in neurological function.
• Step therapy protocol: A process or requirement that a patient first tries a lower-cost or stepwise treatment before a more expensive or alternative therapy.
• FDA-approved drug: A medication that has received approval from the U.S. Food and Drug Administration for a specific labeled use.
• Prescription drug formulary: The list of medications that a health plan covers.
• Clinical practice guideline: A formal set of recommendations for clinical care, as defined in the referenced section of law.
• Health plan: A health insurance plan that covers treatment for neurological conditions.

Main Provisions

• Prohibition on step therapy for neurological conditions: A health plan may not limit or exclude coverage for an FDA-approved drug on its formulary by requiring an enrollee with a neurological condition to follow a step therapy protocol, as long as the drug’s use aligns with:
  • the FDA-approved indication, and
  • a relevant clinical practice guideline.
• Scope: The prohibition applies specifically to treatment for neurological conditions and the use of FDA-approved drugs listed on the plan’s formulary.

What this bill aims to accomplish

• Ensure timely access to FDA-approved treatments for neurological conditions by removing barriers created by step therapy protocols.
• Align coverage decisions with established medical guidelines and official drug indications to improve patient care and avoid unnecessary delays in treatment.

Significant Changes to Existing Law

• Adds a prohibition within Minnesota Statutes chapter 62Q that health plans cannot require step therapy for neurological conditions when FDA-approved drugs on the formulary meet approved indications and guideline-based care. This represents a shift toward patient access to recommended therapies without mandatory stepwise prior authorization for neurological conditions.

Implementation Context

• The changes would be codified as new law within Minnesota Statutes chapter 62Q, impacting how health plans administer coverage for neurological treatments.

Relevant terms - step therapy protocol - neurological condition - FDA (U.S. Food and Drug Administration) - FDA-approved indication - prescription drug formulary - clinical practice guideline - enrollee - health plan